Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has announced the appointment of Christopher Bouton, Ph.D., as its new Chief Technology Officer. In this role, Bouton will lead the strategy and development of a next-generation, integrated model-informed drug development (MIDD) platform powered by generative AI and advanced biosimulation technologies. Bouton joins Certara with a strong track record in artificial intelligence and drug development. He founded and served as CEO of Vyasa Analytics, a company acquired by Certara in 2022. Vyasa specialized in scalable deep-learning software that enables Certara’s platforms to generate insights from both structured and unstructured data. Under Bouton’s leadership, Certara has launched several AI-driven products, including CoAuthor™, a generative AI tool designed to streamline regulatory and medical writing. Prior to Vyasa, Bouton founded and led Entagen, an enterprise analytics software company acquired by Thomson Reuters. He began his career as a computational biologist at Pfizer, where he contributed to early drug discovery efforts. “Chris is a visionary leader who brings deep expertise in AI and firsthand experience in drug discovery and development,” said William F. Feehery, CEO of Certara. “His leadership has been pivotal in expanding the use of AI-powered biosimulation and virtual trials, helping clients accelerate the path to market for new medicines with greater confidence and efficiency.” Certara’s next-generation platform unifies its scientific knowledge, extensive suite of software solutions, and cutting-edge AI capabilities to enhance the speed, accuracy, and success rate of drug discovery and development. By integrating biosimulation with machine learning and generative AI, the platform enables researchers to make data-driven decisions earlier in the process, reduce clinical trial risks, and lower development costs. “Biosimulation, when combined with generative AI and machine learning, is transforming how medicines are discovered and developed,” said Bouton. “Leading the technology strategy at Certara to build the most advanced AI-powered MIDD platform presents a unique opportunity to push the boundaries of science and deliver better outcomes for patients around the world.” Certara serves more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. The company continues to drive innovation in model-informed drug development through its software, technology, and expert services. For more information, visit certara.com. Media Contact: Alyssa Horowitz, [email protected] Investor Relations: Sheila Rocchio, [email protected]